BMS issues PK notice regarding ATV + TDF.
D000225:Adenine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019540:Area Under Curve; D000069446:Atazanavir Sulfate; D002986:Clinical Trials as Topic; D004345:Drug Industry / Q000458:organization & administration*; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000068698:Tenofovir; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D009842:Oligopeptides; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D011725:Pyridines; D000069446:Atazanavir Sulfate; D000068698:Tenofovir; D000225:Adenine